AstraZeneca said Friday it plans to apply for regulatory approval of an antibody cocktail that a preliminary study showed was highly effective in preventing symptomatic COVID-19, offering a potential alternative or complement to vaccines.
The Anglo-Swedish drugmaker announced in an Aug. 20 release that the drug, a combination of two long-acting antibodies derived from convalescent plasma, reduced the risk of symptomatic COVID-19 by 77 percent in a clinical trial.
